Advertisement

Topics

Alkermes Initiates NDA Submission Of ALKS 5461 For Major Depressive Disorder

07:33 EDT 21 Aug 2017 | FinanzNachrichten

WASHINGTON (dpa-AFX) - Alkermes plc (ALKS), a biopharmaceutical company focused on the central nervous system or CNS, diseases, announced Monday the initiation of its rolling submission of a New D...

Original Article: Alkermes Initiates NDA Submission Of ALKS 5461 For Major Depressive Disorder

NEXT ARTICLE

More From BioPortfolio on "Alkermes Initiates NDA Submission Of ALKS 5461 For Major Depressive Disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...